MRA.PDF (51.58 kB)
Technology evaluation: MRA, Chugai
journal contributionposted on 2023-05-26, 15:59 authored by Ding, C, Jones, G
Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
Publication titleCurrent Opinion in Molecular Therapeutics